- Home
- MESO vs CCEC Comparison
MESO vs CCEC Comparison
Compare MESO & CCEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- CCEC
- Stock Information
- Founded
- MESO 2004
- CCEC 2007
- Country
- MESO Australia
- CCEC Greece
- Employees
- MESO N/A
- CCEC N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- CCEC Marine Transportation
- Sector
- MESO Health Care
- CCEC Consumer Discretionary
- Exchange
- MESO Nasdaq
- CCEC Nasdaq
- Market Cap
- MESO 1.4B
- CCEC 1.4B
- IPO Year
- MESO N/A
- CCEC 2007
- Fundamental
- Price
- MESO $10.44
- CCEC $24.14
- Analyst Decision
- MESO Buy
- CCEC Buy
- Analyst Count
- MESO 4
- CCEC 2
- Target Price
- MESO $18.00
- CCEC $24.00
- AVG Volume (30 Days)
- MESO 191.2K
- CCEC 10.7K
- Earning Date
- MESO 02-26-2025
- CCEC 08-01-2025
- Dividend Yield
- MESO N/A
- CCEC 2.52%
- EPS Growth
- MESO N/A
- CCEC 44.72
- EPS
- MESO N/A
- CCEC 3.36
- Revenue
- MESO $5,670,000.00
- CCEC $402,628,000.00
- Revenue This Year
- MESO $178.09
- CCEC $19.03
- Revenue Next Year
- MESO $305.06
- CCEC $13.94
- P/E Ratio
- MESO N/A
- CCEC $7.09
- Revenue Growth
- MESO N/A
- CCEC 69.94
- 52 Week Low
- MESO $5.78
- CCEC $14.09
- 52 Week High
- MESO $22.00
- CCEC $24.33
- Technical
- Relative Strength Index (RSI)
- MESO 40.14
- CCEC N/A
- Support Level
- MESO $11.70
- CCEC N/A
- Resistance Level
- MESO $12.37
- CCEC N/A
- Average True Range (ATR)
- MESO 0.44
- CCEC 0.00
- MACD
- MESO -0.04
- CCEC 0.00
- Stochastic Oscillator
- MESO 6.88
- CCEC 0.00
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.